Why the study?
Improved breast cancer survival has shifted focus to treatment-related long-term effects and quality of life, as shared risk factors and cancer therapies place survivors at increased risk for cardiovascular disease and related mortality.
Breast cancer survivors face increased cardiovascular morbidity and mortality due to shared risk factors and cardiotoxic cancer therapies, highlighting the need for multidisciplinary cardio-oncology care.
Underscores need for cardio-oncology integration in breast cancer care; leaves open optimal monitoring protocols pending prospective trials.
Cardiovascular disease (CVD) and breast cancer cause substantial morbidity and mortality in women and are major public health concerns. Breast cancer survivors are at a greater risk for CVD-related mortality compared to women without breast cancer. Breast cancer and cardiovascular diseases share a number of common risk factors. Breast cancer treatments like anthracycline based chemotherapy, novel targeted therapy and radiation therapy can cause cardiotoxicity. With improvements in breast cancer prevention and treatment, there is a significant improvement in survival and this shifts focus from disease control to long term effects of treatment and quality of life. Assessing CVD and minimizing complications from cancer therapy are important treatment goals.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: